RATIONALE: Estrogen can stimulate the growth of cancer cells. Letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: Phase IV trial to study the effectiveness of letrozole in treating postmenopausal women who have metastatic breast cancer that has been previously treated with tamoxifen.
OBJECTIVES: I. Determine the time to progression of postmenopausal women with metastatic breast cancer treated with letrozole (Femara) as first-line therapy. II. Determine the objective response rate, time to treatment failure, survival rate, and changes in symptom distress in patients treated with this regimen. OUTLINE: This is a multicenter study. Patients are stratified according to time to diagnosis of metastatic disease. Patients receive oral letrozole (Femara) daily. Treatment continues in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 590 patients will be accrued for this study.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Alta Bates Comprehensive Cancer Center
Berkeley, California, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Long Beach Memorial Breast Center
Long Beach, California, United States
Cancer Research Network, Inc.
Hollywood, Florida, United States
Oncology-Hematology Group of South Florida
Miami, Florida, United States
Pharm Research
Pinecrest, Florida, United States
Cancer Research Network Inc.
Plantation, Florida, United States
Good Samaritan Medical Center
West Palm Beach, Florida, United States
Illinois Oncology, Ltd.
Belleville, Illinois, United States
Joliet Oncology/Hematology Associates, Ltd.
Joliet, Illinois, United States
Memorial Medical Center
Springfield, Illinois, United States
...and 10 more locations